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Summary 
The effects of treatment with a monodonal antibody (R73 mAb) against T cell receptor o~/~/ 
(TCR-c~/B) on both established adjuvant arthritis (EAA) and established collagen-induced arthritis 
(ECIA) in rats have been investigated. Rats were treated with R73 mAb when arthritis reached 
a peak. Treatment with the anti-TCR-cff~/mAb markedly suppressed EAA, whereas ECIA was 
not affected by the mAb treatment. Histologically, R73 mAb-treated rats with EAA showed 
mild hyperplasia of synovial tissues, sparse infiltration of  inflammatory  ceils, and minimal erosion 
of cartilage, whereas arthritic rats treated with PBS and an irrelevant control mAb against Giardia 
had marked hyperplasia of synovium with pannus, massive inflammatory  cell infiltrate, and severe 
destruction of cartilage  and subchondral  bone.  R73 mAb-treated rats with ECIA exhibited 
pronounced formation of pannus containing many inflammatory cells and marked cartilage and 
subchondral damage similar to those in arthritic rats that received  the control treatments. Treatment 
with R73 mAb depleted markedly cr  + T cells in both peripheral blood and synovial tissues 
of rats with EAA and ECIA. R73 mAb treatment was associated with marked reduction in 
arthritogen-specific delayed-type hypersensitivity responses in both EAA and ECIA. The titers 
of antibodies against type II collagen produced in rats with ECIA were not affected by the mAb. 
Thus, c~/~ + T  cells appear to have a central role in EAA, but not in chronic ECIA. 
l~ 
eumatoid  arthritis  (RA)  1 is  a  chronic  destructive 
inflammatory joint  disease for which key inducing 
agents have not been identified. Although a number of in- 
vestigations have shown that T cells are a prominent cell in 
rheumatoid synovium (1-3), humoral factors including rheu- 
matoid factor and anti-type II collagen antibodies are also 
prominent and there is no direct evidence that implicates T 
cells as a necessary participant  in the established or postin- 
duction phase of the disease. 
Both adjuvant arthritis (AA) and collagen-induced arthritis 
(CIA) in rats are experimental models of polyarthritis  that 
resemble RA in certain clinical and histological aspects (4, 
5).  AA and CIA can be induced by immunization with 
Myrobacteriura tuberculosis (MT) (4) and native type II col- 
lagen (CII) (5), respectively, and are believed to be mediated 
by T cells. For instance, lymph node and spleen cells from 
rats primed with MT and CII passively transfer AA (6) and 
CIA (7), respectively, to naive recipient rats, although the 
recipients develop a less persistent,  milder arthritis  than is 
1 Abbreviations used in tkis paper: AA, adjuvant arthritis;  CIA, collagen- 
induced arthritis; CII, type II collagen; DTH, delayed-type  hypersensitivity; 
E, established; MT, Mycobacteriura tuberculosis; RA, rheumatoid  arthritis. 
observed in rats immunized actively with the antigens. T cell 
lines and clones specific  for MT (8) and CII (9) can also cause 
mild transient  arthritis.  These studies indicate that T cells 
are necessary for the induction of the both forms of arthritis, 
but do not examine directly the role of T cells in the estab- 
lished diseases. To determine whether T cells have a role in 
established AA (EAA) and established CIA (ECIA), we have 
assessed the effects on these diseases of a mAb (R73 mAb) 
against a constant determinant of TCR-c~/3 that is expressed 
on 97% of rat peripheral blood T cells (10). We report here 
that the depletion of ot/3 + T cell by treatment with R73 
mAb suppressed EAA, while ECIA was not affected by the 
mAb, indicating that T cells play a crucial role in EAA, but 
not in ECIA. 
Materials and Methods 
Animals.  Inbred  female  Dark Agouti rats weighing 90-100 g 
were  purchased  from GiUes  Plains Animals Resource  Center (Gilles 
Plains, South Australia). They were housed five per cage and fed 
standard rodent chow (Milling Industries, Dulwich, South Aus- 
tralia) and water ad libitum. 
Induction of AA and CIA.  AA was induced by an intradermal 
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MT (K73Ra; Difco Laboratories,  Detroit, MI). To induce CIA, 
8 mg of CII extracted from native calf articular cartilage (Elastin 
Products, MO) was dissolved in 1 ml of 0.01 M acetic acid and 
emulsified  with an equal volume of IFA. 0.1 ml of the emulsion 
was injected into the tail base. AA was established by day 14 and 
CIA by day 20 after injection of the appropriate arthritogen. To 
evaluate the severity of arthritis, the lesions of the four paws were 
each graded from 0 to 4 according to the increasing extent of ery- 
thema and edema of the periarticular tissue as described by Wood 
et al.  (11). The maximum possible  score is 16. 
Treatment with R73 mA~  The cell line of a mouse mAb (R73 
mAb)  against  the  constant  determinant  of TCR-cffB  kindly 
provided by Dr.  T.  H~inig  (Wiirzburg,  FKG).  R73  mAb was 
purified from ascitic  fluid  according to the method of Ey et al. 
(12). The preparation and characterization of R73 mAb have been 
described previously (10). 100 gg of K73 mAb dissolved in 1 ml 
of PBS was injected intraperitoneally on days 14,  15,  16, 17,  18, 
20, and 22 in rats with EAA, and on days 20, 21, 22, 23, 24, 26, 
and 28 in rats with ECIA. To assess whether the induction of both 
AA and CIA is blocked by treatment with K73 mAb, the anti- 
body was given every 3 d from the time of immunization with 
MT and CII up to days 21 (AA) and 27 (CIA), respectively.  As 
treatment controls, 1 ml of PBS only and I ml of PBS containing 
100 #g of a mouse mAb (1B5 mAb) against  Giardia (Department 
of Microbiology and Immunology, University of Adelaide, Adelaide, 
Australia),  which is the same isotype (IgG1) as K73 mAb but has 
irrelevant specificity, were given to comparable groups of rats  at 
the above times. 
Histology.  Rats with EAA were killed on day 14 (before K73 
mAb treatment) and day 24 (after treatment), and rats with ECIA 
were killed on day 20 (before treatment) and day 30 (after treat- 
ment).  Hind paws  were amputated,  fixed in 4%  formalin, and 
decalcified in a solution of 3.1% HCI, 5% formic acid, and 7% 
aluminium chloride. The tissues were embedded in paraffin,  sec- 
tioned at 4 #m,  and stained with hematoxylin and eosin. 
Detection of Pe@heral Blood c~/3 + T Cells.  A small volume of 
blood was withdrawn immediately before the next injection of K73 
mAb from the tail vein for preparation of smears on days 14, 18, 
and 24 after immunization with MT and on days 20, 24, and 30 
after immunization with CII. To detect c~/B + and CD5 + T cells, 
smears  were incubated with  R73 and OX19 mAbs  (anti-CDS; 
Department  of Microbiology and  Immunology,  University of 
Adelaide, Adelaide, Australia),  respectively, and bound antibodies 
were revealed using F(ab')2 fragments of sheep anti-mouse IgG an- 
tibody (Sigma  Chemical Co., St. Louis,  MO) and complexes of 
alkaline phosphatase and a murine mAb against alkaline phospha- 
tase (APAAP;  Boehringer Mannheim, North Kyde, New South 
Wales, Australia)  according to the method of Cordell et al. (13). 
Fast red was used as a capture agent to detect cells labeled by APAAP 
and hematoxylin was the counterstain. The percentage of leuko- 
cytes binding R73 and OX19 mAb was determined. 
Immunohistology.  To determine whether ol/B + T  cells in sy- 
novial tissues of rats with EAA and ECIA are depleted by treat- 
ment  with  K73  mAb,  100  /~g  of  the  mAb  was  given  in- 
traperitoneally into five rats on days 14-17, and on days 20-23 after 
immunization with MT and CII, respectively. PBS and 1B5 mAb 
were given to treatment control rats. The animals were killed 7 h 
after the last injection of K73 mAb or control treatment, and ankle 
joints were amputated. The ankle joints were immersed in an EDTA 
solution for decalcification according to the method ofJonsson et 
al. (14) and frozen for the preparation  of 7/xm cryosections, ot//~ + 
and CD5 § (OX19 mAb +) T cells in the joint synovial tissues were 
detected by the APAAP method as described above. 
Induction of Delayed-Type Hypersensitivity (DTH).  20 #g of MT 
suspended  in 50 #1 of PBS and 20 #g of CII dissolved in 50 #1 
of 0.001 M acetic acid was injected subcutaneously into the right 
ear on day 18 in rats immunized with MT and on day 24 in rats 
immunized with CII, respectively.  As vehicle controls, 50 #1 of 
PBS or 50 #1 of 0.001  M acetic acid alone was injected into the 
left ear. The thickness of the right and left ears were measured 
using dial  gauge calipers  calibrated  with 0.01-mm graduations 
(Mitutoyo, Japan) immediately before and 48 h after the challenge 
injection of MT or CII. There was minimal ear swelling after 48 h 
in response to MT and CII in nonimmunized rats.  The increase 
in left ear thickness was subtracted from the increase in right ear 
thickness, to determine swelling attributable to the specific response 
to antigen. 
Measurement of  Anti-CIIAntibody.  Blood was collected on days 
20,  25,  and 30 after immunization with CII as described  above. 
Sera were heat inactivated at 56~  for 30 min, and stored at -20~ 
until assayed. Anti-CII antibody was measured using an ELISA 
(15). In brief, 96-well flat-bottomed microtiter plates were incubated 
with 100 #l/well of CII (20 #g/ml) at 37~  for 1 h and washed 
three times with PBS containing 0.05% Tween 20. The wells were 
then blocked by incubation with 200 #1 of PBS containing 1% 
BSA at 37~  for 1 h.  After washing,  the plates  were incubated 
with 100 #l/well of twofold dilutions of pooled rat sera at 37~ 
for 30 min. The plates were washed, and 100 #l/well of a 1:250 
dilution of sheep anti-rat IgG labeled with ~-galactosidase  (Amer- 
sham, North Ryde, NSW, Australia)  was added and incubated at 
37~  for 30 min. After washing, 100 #1 of 3 mM o-nitrophenyl-/$- 
D-galactopyranoside (Amersham) was added per well and the plates 
were incubated in the dark at room temperature for 30 min. The 
absorbance was then measured at 410 nm in a Titertec ELISA reader 
(Flow Laboratories, North Kyde, NSW, Australia). Antibody titers 
were expressed as  -log2 dilution at which an absorbance of two 
times control (omitting rat serum) was  obtained. 
Results 
Effect of R73 mAb on EAA and ECIA.  EAA developed 
by day 14 after immunization with MT (Fig. 1 A). Rats given 
repeated injections of PBS and  1B5 mAb  from day  14 ex- 
hibited persistent active disease. In contrast, one injection of 
K73 mAb  on day  14 had  significantly suppressed  existing 
arthritis 24 h later. Marked progressive suppression of arthritis 
followed the further administration of K73 mAb on days 15, 
16,  17,  18,  20,  and  22. 
Typically, ECIA became evident on day 20 after immuni- 
zation with CII (Fig.  1 B). Treated rats with R73 mAb on 
days 20, 21, 22, 23, 24, 26, and 28 followed the same course 
of disease as their counterparts treated with PBS and 1B5 mAb. 
When  rats were treated with  R73  mAb  from the time 
of immunization with MT and CII, the induction of both 
AA  and  CIA was blocked completely (Fig.  2, A  and B). 
Effect of R73 mAb on Histologic Changes in Tarsal  Joints of 
Rats with EAA andECIA.  The effect of K73 mAb on EAA 
and ECIA was assessed by examining histologic changes be- 
fore and after the mAb treatment period. In rats killed im- 
mediately before the treatment period, i.e., on day 14 in EAA 
rats (Fig. 3 A) and on day 20 in ECIA rats (Fig. 4 A), the 
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Figure 1.  Comparison of the effects of K73 mAb on EAA and ECIA. 
PBS, 1B5 mAb, and R.73 mAb were administered on days 14, 15, 16, 17, 
18, 20, and 22 (arrows) after inoculation of MT (.4), and on days 20, 21, 
22, 23, 24, 26 and 28 (arrows) after immunization  with CII (B). (e) PBS; 
(A) 1B5 mAb; (O) K73 mAb. Vertical bars show SEM of five rats. R73 
mAb treatment compared with PBS and 1B5 mAb treatment (student's 
t test,  *p <  0.01). 
joints exhibited  synovial edema with infiltration  of many 
inflammatory cells, induding neutrophils  and mononuclear 
cells, but only minimal erosion of cartilage. When assessed 
after treatment, PBS- and 1B5 mAb-treated rats with EAA 
(day 24, Fig. 3 B) and ECIA (day 30, Fig. 4 B) had developed 
pronounced pannus, dense inflammatory cell infiltrate in which 
mononudear cells predominated, and severe destruction of 
cartilage and subchondral bone. Treatment of EAA with K73 
mAb suppressed markedly  pannus formation and infiltration 
of inflammatory cells and prevented the damage of cartilage 
and bone (Fig. 3 C). In contrast, R73 mAb-treated rats with 
ECIA developed chronic erosive synovitis (Fig. 4 C) similar 
to that seen in animals injected with PBS and 1B5 mAb. 
Effect of R73  mAb on the Percentage of c~/f3 + and CD5 § 
T  Cells  in  Peripheral Blood  in  Rats  with EAA  and ECIA. 
ot/~ + and CD5 + T cells in peripheral blood of rats treated 
with PBS, 1B5 mAb, and K73 mAb were examined on days 
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Figure 2.  Prevention of the induction of AA and CIA by K73 mAb. 
PBS, 1B5 mAb, and K73 mAb were administered every 3 d from the time 
of immunization  with MT (A) and CII (B) up to days 21 and 27, respec- 
tively. (e) PBS; (A) 1B5 mAb; (O) K73 mAb. Vertical bars show SEM 
of five rats. 
14, 18, and 24 in rats with EAA, and on days 20, 24, and 
30 in rats with ECIA. 35-45%  of leukocytes were K73 + 
and  OX19 + before  treatment and  throughout treatment 
with PBS or 1B5 mAb irrespective of the arthritogen used 
(Table 1). In contrast, TCR-ot/~ and CD5 + T cells in R73 
mAb-treated rats with EAA and ECIA constituted ",~5% 
of leukocytes. 
Effect of R73 mAb on the Depletion of o_/B + and CD5 + T 
Cells in Synovial Tissues of  Rats with EAA and ECIA.  A large 
number of ot/B + and CD5 + T  cells were present in syno- 
vial tissues of rats with EAA and ECIA treated with either 
PBS or 1B5 mAb on days 17 and 23, respectively. Typical 
findings are shown in Fig. 5 A. There was no significant differ- 
ence in the positive cell numbers between EAA and ECIA. 
In contrast, there was a marked reduced number of synovial 
tissue ot//~  + and CD5 + T  cells in R73 mAb-treated rats 
with EAA and ECIA (Fig. 5 B). Cells in synovial tissues 
as well as in peripheral blood from K73 mAb-treated rats 
were not stained with the secondary antibody (not shown). 
909  Yoshino and Cleland Figure 3.  Histologic changes in tarsal  joints 
of rats  with EAA after treatment with R73 
mAb. Tarsal  joints of rats with EAA were ex- 
amined immediately before commencement of 
the R73 mAb treatment period on day 14 (A) 
and after treatment with PBS or 1135 mAb (B) 
and  with  R73  mAb  (C)  on  day  24.  H&E 
stained,  xl00. 
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Figure 4.  Histologic changes in tarsal  joints 
of rats with ECIA after treatment with K73 
mAb. Tarsal  joints of rats with ECIA were e~- 
amined immediately before commencement  of 
the K73 mAb treatment period on day 20 (A) 
and after treatment  with PBS or 1B5 mAb (B), 
and  with  R73  mAb  (C)  on  day  30.  H&E 
stained,  xl00. Table  1.  Depletion of ot/B + and CD5 ÷ T  Cells by R73  mAb in Pe@heral Blood in Rats with EAA  and ECIA 
otI  3 + leukocytes  CD5*  leukocytes 
Group  Day  PBS  1B5  mAb  K73  mAb  PBS  1B5  mAb  K73  mAb 
%  % 
14  33  ±  2.7  35  ±  2.3  33  ±  3.1  36  ±  3.2  35  ±  2.6  36  ±  3.6 
EAA  18  35  ±  3.0  37  ±  2.8  2  ±  2.7*  34  ±  2.8  35  ±  3.0  3  ±  3.1" 
24  38  ±  3.3  40  ±  3.1  6  ±  3.0*  41  ±  3.5  42  ±  3.3  6  _+.  3.6* 
20  43  ±  4.0  40  ±  3.2  42  ±  4.1  41  ±  3.5  43  ±  3.5  42  ±  3.8 
ECIA  24  41  ±  3.8  40  ±  2.8  3  ±  3.3*  45  ±  4.4  40  ±  3.2  3  ±  2.9* 
30  45  ±  4.2  44  +_  3.0  5  ±  4.9*  45  ±  4.0  42  ±  3.5  7  +  3.4* 
PBS, 1B5 mAb, and R73 mAb were administered  on days 14,  15,  16,  17,  18,  20,  and 22 after inoculation  of MT, and on days 20,  21,  22,  23, 
24,  26, and 28 after immunization with CII. The percentages  of ~/3+  and CD5 ÷ T cells in peripheral leukocytes from rats with EAA and ECIA 
were determined  by preparing  blood smears immediately before the scheduled injection of R73 mAb on the days indicated.  Values are expressed 
as mean  +_  SEM of five rats.  R73 mAb treatment compared  with PBS and  1B5 mAb treatment (student's  t test,  *p <  0.01). 
Effect of R73 mAb on DTH Responses to MT and CII in 
Rats with EllA and ECIA, Respectively.  To examine the effect 
of  c~/3 +  T  cell  depletion  on  cell-mediated  immune  re- 
sponses,  the  ear  DTH  responses  to  MT  and CII  in  R73 
mAb-treated rats with EAA and ECIA, respectively,  were 
determined.  As  shown in  Table  2,  R73  mAb-treated  rats 
showed markedly reduced DTH responses to the respective 
immunizing  agents  compared  with  their  PBS-  and  1B5 
mAb-treated counterparts. 
Effect of R73 mAb on Production of  Antibodies to (211 in Rats 
with ECIA.  To determine whether tL73 mAb treatment 
affected  established antibody levels, anti-CII antibody titers 
were determined in ECIA rats. The results showed that there 
was no significant  difference in titers  of antibodies  to CII 
on days 20, 25, and 30 after immunization with CII between 
PBS-,  1B5  mAb-  and R73  mAb-treated  rats  (Table  3). 
Table  2.  Effect of R73  mAb on the DTH Responses to MT and 
CII in Rats with EAA  and ECIA,  Respectively 
Increase in ear thickness 
Group  PBS  1B5  mAb  R73  mAb 
× 10 -e mm 
EAA  72  ±  6.8  66  ±  5.7  15  ±  3.0* 
ECIA  101  ±  7.5  91  ±  8.3  22  ±  3.7* 
PBS, 1B5 mAb, and R73 mAb were administered  on days 14,  15,  16, 
17,  18,  20,  and  22 after  inoculation  of MT, and  on days 20,  21,  22, 
23, 24, 26, and 28 after immunization with CII. The ear DTH responses 
to MT in rats with EAA and to CII in rats with ECIA were tested on 
days 18 and 24, respectively, as described in Materials and Methods. Values 
are expressed as mean  +  SEM of five rats.  R73 mAb treatment com- 
pared with PBS and  1B5 mAb treatment (student's  t test,  *p <  0.01). 
Discussion 
A  role for T  cells in the induction of AA and CIA has 
been established (6-9). However, the influence of T cells in 
maintaining established arthritis in these models has not been 
critically examined. In the present studies, arthritogen-specific 
cell-mediated immune responses were reduced markedly in 
R73 mAb-treated rats with EAA and ECIA, as evidenced 
by significantly suppressed DTH responses to MT and CII, 
respectively. However, od3 + T cells may exert a crucial sus- 
taining effect on the course of EAA, but not in ECIA, since 
the depletion of ot/B + T  cells by R73 mAb against TCR- 
ot/B markedly suppressed EAA, but did not affect the progres- 
sion of ECIA. 
The mechanism of progression of ECIA is not clear at 
present. Antibodies to CII may be a potentially critical factor 
after the disease is established.  Polyarthritis can be transferred 
passively to naive recipient rats with anti-CII antibodies (16), 
although the disease is transient and a role for the humoral 
Table  3.  Effect of R73  mAb on  the Production of Antibodies  to 
CII in Rats with ECIA 
Anti-CII antibody  titer 
Day  PBS  1B5  mAb  K73  mAb 
-/og2 
20  10.5  -+  0.43  10.2  ±  0.41  9.8  ±  0.33 
25  11.4  ±  0.42  10.8  ±  0.37  10.6  ±  0.24 
30  11,2  ±  0,51  10.4  ±  0.45  10.6  _+  0.36 
PBS, 1B5 mAb, and R73 mAb were adminstered  on days 20,  21,  22, 
23, 24, 26, and 28 after immunization with CII. Anti-CII antibody titers 
were determined by an ELISA on the days indicated. Values are expressed 
as mean  _+  SEM of five rats. 
912  Role of od3 T  Cells in Established Arthritis Figure 5.  Depletion  ofc~/B  + and CD5 + T ceils 
in synovial  tissues  of rats with EAA and ECIA by 
R73 mAb. PBS, 1B5 mAb, and R73 mAb were  ad- 
ministered  on days 14-17, and on days  20-23 after 
immunization  with MT and CII, respectively. 7 h 
after the hst dose, odB  + and CD5 + T cells in tarsal 
joints of rats with EAA and ECIA were detected 
by the APAAP method. (A) PBS- or 1B5 mAb- 
treated rats with ECIA; (B) R73 mAb-treated  rats 
with ECIA  (x 200). Essentially  similar  findings  were 
obtained with EAA rats. 
response beyond the induction phase of CIA can not be in- 
ferred. There has been no published demonstration that AA 
can be transferred with serum from MT-primed rats. We have 
failed to achieve adoptive transfer of AA to syngeneic naive 
recipient rats with serum from rats with EAA, but have in- 
duced transient polyarthritis in rats by adoptive transfer with 
serum from CII-primed animals (our unpublished data). Es- 
tablished anti-CII antibody levels in rats with ECIA were 
not affected by treatment with R73 mAb, thus allowing a 
contribution by anti-CII antibodies to the persistent destructive 
arthritis in R73 mAb-treated animals. 
We have shown previously (17, 18) and also in the part 
of the present studies that rats treated with K73 mAb from 
the time of immunization with MT and CII do not develop 
polyarthritis. The present studies were designed to evaluate 
the role of T  cells in the mediation of established  disease in 
these two models of arthritis. The findings suggest that AA 
is T  cell dependent in both induction and maintenance of 
disease, while T  cells have a role in induction of CIA, but 
may not be required for maintenance of the established  dis- 
ease. T  cells are needed to induce the humoral response to 
CII since anti-CII antibody production is T  cell dependent 
(19), but once this response  is established,  T  cells may not 
be required to sustain antibody level,  at least  in the short 
term. Thus, ECIA might be antibody dependent, but not 
dependent on the continuing participation of T cells beyond 
the induction phase. 
A large number of T  cells are present in inflamed syno- 
vium of rats with AA (20) and CIA (21). The present im- 
munohistological investigations confirmed the infiltration of 
many cff~  +  and CD5 + T  cells  in  synovial tissues  in the 
both forms of arthritis. T  cells are also a prominent cell in 
913  Yoshino  and Clehnd synovial tissues of  patients with RA (1-3). However, the pres- 
ence of T  cells does not necessarily implicate a direct role 
for T cells in maintaining existing arthritis as shown by the 
difference in effect of the anti-TCK-od/~ mAb on EAA and 
ECIA in the present studies. After intraperitoneal  injection 
of R73 mAb, the mAb can be expected to enter the inflamed 
synovium and bind TCR-a/~  expressed on synovial a//3 + 
T cells of rats with either EAA or ECIA. The results indi- 
cating that EAA was suppressed significantly within 24 h 
after administration  of R73 mAb suggest a direct effect of 
the mAb on arthritogenic T cells in synovial tissues. In addi- 
tion, the effect of K73 mAb therapy on the recruitment of 
T cells into synovium is suggested by the observed depletion 
of synovial o~/B  + and CD5 + T  cells. To our knowledge, 
this is the first demonstration that a mAb therapy for ar- 
thritis depletes inflamed synovial tissue T  cells. 
The proportionate depletion of CD5 + and R73 + T cells 
in  peripheral  blood  as  well  as  synovial  tissues in  K73 
mAb-treated rats excludes the possibility that modulation 
of TCR-c~/B by R73 mAb might render crib + T cells un- 
detectable without causing depletion. Cells coated with R73 
mAb in vivo could not be detected in either peripheral blood 
or synovial tissues from R73 mAb-treated rats with EAA 
and ECIA by application  of the secondary antibody and 
revealing agents. K73 mAb is of the IgG1 isotype and there- 
fore should not fix complement. A relatively weak comple- 
ment-fixing IgG2a mAb against Thy-l.2 efficiently  eliminated 
Thy-l.2 cells from the blood of mice in vivo and was shown 
to opsonize Thy-l.2-bearing cells for phagocytosis in vitro 
(22). Therefore, it seems likely that opsonization  and clear- 
ance by the reticuloendothelial  system is the mechanism for 
the T cell depletion caused by this mAb. A similar mecha- 
nism could account for the T cell-depleting effect  of  K73 mAb. 
K73 mAb depletes specifically  ot/~ + T cells, but does not 
affect y/t3+  T cells (10). y/t3 + T cells respond to MT (23) 
and heat-shock proteins (24), and have been found in syno- 
vial fluid in RA (25), Accordingly, a role for 3,//5  + T cells 
in RA and animals models of arthritis such as EAA and ECIA 
needs to be considered. In the case of ECIA, the lack of effect 
of or//3  + T cell depletion by R73 mAb allows the possibility 
that 3,/t3  + T cells could be contributing to the maintenance 
of ECIA.  A  role for 3,/t3  + T  cells is less likely in EAA, 
which is markedly suppressed by R73 mAb treatment. How- 
ever, it remains possible that 3~/t3  § T cells might have a role 
in the presence of oz//3  + T cells. A more precise definition 
of the role of 3,/t3 + T cells in these models of polyarthritis 
awaits the development of mAbs against the TCR-'y/t3 that 
can be used to assess the effect of y/t3+ T cell depletion on 
disease induction and expression. 
Both AA (4) and CIA (5) resemble RA in many impor- 
tant respects. However, it is not clear which model more 
reliably reflects the pathological process occurring in estab- 
lished RA. mAbs against CD4 (26, 27) and IIr  (28) have 
recently been shown to have a beneficial effect on RA, al- 
though not all subjects have responded and the number of 
patients treated with these antibodies is small. These studies 
suggest that T cells play a central role in at least some cases 
of established RA as occurs in EAA. On the other hand, 
an important involvement of the humoral response in RA 
has also been argued.  For instance, a large amount of au- 
toreactive Ig is produced by rheumatoid synovium (29) and 
the low levels of complement activity in rheumatoid syno- 
vial  fluid  suggests  consumption of complement by local 
antigen-antibody complexes (30). Further evaluation of  treat- 
ment with anti-TCR  mAbs should provide further under- 
standing of the key pathogenic events in established RA, in- 
cluding better definition of the respective roles of humoral 
and cell-mediated immune responses. Indeed, specific anti-T 
cell reagents could allow more precise categorization  of RA 
into subtypes defined by their apparent  dependence upon 
different T  cell subpopulations. 
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